Suchergebnisse - "Sodium-Glucose Transporter 2 Inhibitors/adverse effects"
-
1
Autoren: et al.
Quelle: Adv Ther
Schlagwörter: Male, Heart Failure, ddc:610, Middle Aged, Benzhydryl Compounds/therapeutic use [MeSH], Sodium-Glucose Transporter 2 Inhibitors/therapeutic use [MeSH], Aged [MeSH], Diabetes Mellitus, Type 2/drug therapy [MeSH], Randomized Controlled Trials as Topic [MeSH], Hypoglycemic Agents/adverse effects [MeSH], Male [MeSH], Adverse drug event, Hypoglycemic Agents/therapeutic use [MeSH], Glucosides/adverse effects [MeSH], Original Research, SGLT2 inhibitors, Sodium-Glucose Transporter 2 Inhibitors/adverse effects [MeSH], Adverse drug reaction, Female [MeSH], Benzhydryl Compounds/adverse effects [MeSH], Diabetes Mellitus, Type 2/complications [MeSH], Humans [MeSH], Drug safety, Cardiovascular Diseases [MeSH], Heart Failure [MeSH], Middle Aged [MeSH], Renal Insufficiency, Chronic [MeSH], Glucosides/therapeutic use [MeSH], Empagliflozin, Glucosides, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Humans, Hypoglycemic Agents, Female, Benzhydryl Compounds, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, Aged, Randomized Controlled Trials as Topic
Dateibeschreibung: application/pdf
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38771475
https://repository.publisso.de/resource/frl:6508947
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-398088
https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/39808
https://doi.org/10.1007/s12325-024-02879-w
https://opus.bibliothek.uni-wuerzburg.de/files/39808/12325_2024_Article_2879.pdf -
2
Autoren: et al.
Quelle: Clin Exp Nephrol
Schlagwörter: Male, Kidney, 01 natural sciences, 03 medical and health sciences, 0302 clinical medicine, Glucosides, Japan, Double-Blind Method, Humans, Albuminuria, Renal Insufficiency, Chronic, Benzhydryl Compounds, 0101 mathematics, Sodium-Glucose Transporter 2 Inhibitors, Aged, Middle Aged, 16. Peace & justice, 3. Good health, Treatment Outcome, Cardiovascular Diseases, Disease Progression, Benzhydryl Compounds/therapeutic use [MeSH], Double-Blind Method [MeSH], Kidney/drug effects [MeSH], Sodium-Glucose Transporter 2 Inhibitors/therapeutic use [MeSH], Renal Insufficiency, Chronic/physiopathology [MeSH], Disease Progression [MeSH], Renal Insufficiency, Chronic/diagnosis [MeSH], Aged [MeSH], Cardiovascular disease, Kidney/physiopathology [MeSH], Male [MeSH], Glucosides/adverse effects [MeSH], Glomerular Filtration Rate/drug effects [MeSH], Kidney Failure, Chronic/drug therapy [MeSH], Sodium-Glucose Transporter 2 Inhibitors/adverse effects [MeSH], Female [MeSH], Benzhydryl Compounds/adverse effects [MeSH], Humans [MeSH], Albuminuria/drug therapy [MeSH], Treatment Outcome [MeSH], Cardiovascular Diseases [MeSH], Middle Aged [MeSH], Japan/epidemiology [MeSH], Glucosides/therapeutic use [MeSH], Kidney function, Rapid Communication, Randomised trial, Sodium–glucose co-transporter-2 inhibitor, Renal Insufficiency, Chronic/drug therapy [MeSH], Kidney Failure, Chronic, Female, Glomerular Filtration Rate
-
3
Autoren: et al.
Quelle: Anaesthesiologie
Schlagwörter: Kasuistiken, Benzhydryl Compounds/therapeutic use [MeSH], Sodium-Glucose Transporter 2 Inhibitors/therapeutic use [MeSH], Cardiac Surgical Procedures/adverse effects [MeSH], Benzhydryl Compounds/adverse effects [MeSH], Ketosis/chemically induced [MeSH], Postoperative Complications/drug therapy [MeSH], Aged [MeSH], Humans [MeSH], Glucosides/therapeutic use [MeSH], Male [MeSH], Glucosides/adverse effects [MeSH], Sodium-Glucose Transporter 2 Inhibitors/adverse effects [MeSH]
Zugangs-URL: https://repository.publisso.de/resource/frl:6522254
-
4
Autoren: et al.
Quelle: Diabetologia
Eleftheriadou, A, Riley, D, Zhao, S S, Austin, P, Hernández, G, Lip, G Y H, Jackson, T L, Wilding, J P H & Alam, U 2024, 'Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database', Diabetologia, vol. 67, no. 7, pp. 1271-1282. https://doi.org/10.1007/s00125-024-06132-5
Eleftheriadou, A, Riley, D, Zhao, S, Austin, P, Hernandez, G, Lip, G Y H, Jackson, T L, Wilding, J P H & Alam, U 2024, 'Risk of Diabetic Retinopathy and Diabetic Macular Oedema with Sodium-Glucose Co-transporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in type 2 Diabetes : A real-world data study from a global Federated Database', Diabetologia.
Eleftheriadou, A, Riley, D, Zhao, S S, Austin, P, Hernández, G, Lip, G Y H, Jackson, T L, Wilding, J P H & Alam, U 2024, 'Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes : a real-world data study from a global federated database', Diabetologia, vol. 67, no. 7, pp. 1271-1282. https://doi.org/10.1007/s00125-024-06132-5Schlagwörter: Male, Diabetes Mellitus, Type 2/drug therapy, Article, Macular Edema, Hypoglycemic Agents/adverse effects, Microvascular Disease, Diabetes Mellitus, Humans, Hypoglycemic Agents, Insulin, Retinopathy, Glucagon-Like Peptide-1 Receptor Agonists/adverse effects, Sodium-Glucose Transporter 2 Inhibitors, Aged, Retrospective Studies, 2. Zero hunger, Diabetic Retinopathy, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, Macular Edema/drug therapy, Middle Aged, Microvascular disease, 3. Good health, Insulin/adverse effects, Type 2/drug therapy, Clinical Diabetes, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Female, Diabetic Retinopathy/chemically induced, Clinical diabetes
Dateibeschreibung: application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38584180
http://www.scopus.com/inward/record.url?scp=85189428328&partnerID=8YFLogxK
https://doi.org/10.1007/s00125-024-06132-5
https://vbn.aau.dk/da/publications/6e3210be-df3a-4c38-8095-c411a9a430b8
https://vbn.aau.dk/ws/files/721108014/Eleftheriadou_et_al._2024_._Risk_of_diabetic_retinopathy_and_diabetic_macular_oedema_with_sodium-glucose_cotransporter_2_inhibitors_and_glucagon-like_peptide_1_receptor_agonists_in_type_2_diabetes_a_real-world_data_study_f.pdf
https://research.manchester.ac.uk/en/publications/a1cfbaf2-d56d-43ea-8487-8e62e730bbe1
https://research.manchester.ac.uk/en/publications/b9b501b2-1980-47e2-a59d-922d3d5a5039
https://doi.org/10.1007/s00125-024-06132-5
https://pure.manchester.ac.uk/ws/files/293928183/171_Diabetologia_Revision_copy.docx
https://research.manchester.ac.uk/en/publications/a1cfbaf2-d56d-43ea-8487-8e62e730bbe1 -
5
Autoren: et al.
Quelle: Rebordosa, C, Thomsen, R W, Tave, A K, Madsen, M, Beachler, D C, Martinez, D, Garcia-Esteban, R, Plana, E, Tormos, A, Farsani, S F, Perez-Gutthann, S & Pladevall-Vila, M 2024, 'Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes : Post-authorization safety study based on multinational cohorts', Diabetes, Obesity and Metabolism, vol. 26, no. 4, pp. 1291-1304. https://doi.org/10.1111/dom.15429
Schlagwörter: Adult, Male, pharmacoepidemiology, Adolescent, Renal Insufficiency, Chronic/complications, empagliflozin, Hypoglycemic Agents/adverse effects, Diabetic Ketoacidosis, Cohort Studies, Glucosides, Acute Kidney Injury/chemically induced, Humans, Hypoglycemic Agents, Dipeptidyl-Peptidase IV Inhibitors/adverse effects, Benzhydryl Compounds, Renal Insufficiency, Chronic, real-world evidence, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Sodium-Glucose Transporter 2 Inhibitors, antidiabetic drug, Dipeptidyl-Peptidase IV Inhibitors, Diabetic Ketoacidosis/chemically induced, Diabetes Mellitus, Type 2/complications, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, Urinary Tract Infections/epidemiology, Acute Kidney Injury, 3. Good health, Diabetes Mellitus, Type 2, Liver, Urinary Tract Infections, Female
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38234181
-
6
Autoren: et al.
Weitere Verfasser: et al.
Quelle: van Hulten, V, Driessen, J H M, Starup-Linde, J K, Al-Mashhadi, Z K, Viggers, R, Klungel, O H, Souverein, P C, Vestergaard, P, Stehouwer, C D A & van den Bergh, J P 2023, 'The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus', Diabetes, Obesity and Metabolism, vol. 25, no. 11, pp. 3235-3247. https://doi.org/10.1111/dom.15220
Schlagwörter: Male, pharmacoepidemiology, Endocrinology, Diabetes and Metabolism, Glucose/therapeutic use, Hypoglycemic Agents/adverse effects, Cohort Studies, Fractures, Bone, Endocrinology, SDG 3 - Good Health and Well-being, Internal Medicine, cohort study, DPP-4 inhibitor, Humans, Hypoglycemic Agents, Dipeptidyl-Peptidase IV Inhibitors/adverse effects, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Sodium-Glucose Transporter 2 Inhibitors, Metformin/adverse effects, Retrospective Studies, Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2/complications, Sodium, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, diabetes complications, SGLT2 inhibitor, Metformin, 3. Good health, Glucose, Diabetes Mellitus, Type 2, Fractures, Bone/epidemiology, Female, type 2 diabetes, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/metabolism
Dateibeschreibung: application/pdf
-
7
Autoren: et al.
Quelle: Jürgens, M, Schou, M, Hasbak, P, Kjær, A, Wolsk, E, Zerahn, B, Brandt-Jacobsen, N H, Gæde, P, Rossing, P, Faber, J, Inzucchi, S E, Gustafsson, F & Kistorp, C 2023, ' The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes ', Diabetes, Obesity and Metabolism, vol. 25, no. 10, pp. 2888-2896 . https://doi.org/10.1111/dom.15183
Schlagwörter: Cardiovascular Diseases/epidemiology, Benzhydryl Compounds/adverse effects, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, heart failure, SGLT2 inhibitor, Type 2/complications, GFR, 3. Good health, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Diabetes Mellitus, Humans, type 2 diabetes, extracellular volume, Plasma Volume, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors, plasma volume, Glomerular Filtration Rate
Dateibeschreibung: application/pdf
-
8
Autoren: et al.
Quelle: Júlíusdóttir, Y K, Halili, A, Coronel, R, Folke, F, Torp-Pedersen, C, Gislason, G H & Eroglu, T E 2023, 'Sodium-glucose cotransporter-2 inhibitors compared with glucagon-like-peptide-1 receptor agonists and out-of-hospital cardiac arrest in type 2 diabetes: a nationwide nested case-control study', European Heart Journal-Cardiovascular Pharmacotherapy, vol. 9, no. 5, pvad033, pp. 437-443. https://doi.org/10.1093/ehjcvp/pvad033
Schlagwörter: Pharmacoepidemiology, Sodium, Out-of-Hospital Cardiac Arrest/diagnosis, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, Glucagon, 3. Good health, Glucose, Diabetes Mellitus, Type 2/diagnosis, Sudden cardiac arrest, Diabetes Mellitus, Type 2, Case-Control Studies, SGLT2-inhibitors, Humans, Sodium-Glucose Transporter 2 Inhibitors, Out-of-Hospital Cardiac Arrest
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37173284
https://vbn.aau.dk/da/publications/4982b72a-91c1-4b03-8628-abd1e793f00f
https://doi.org/10.1093/ehjcvp/pvad033
http://www.scopus.com/inward/record.url?scp=85162135484&partnerID=8YFLogxK
https://pure.amsterdamumc.nl/en/publications/65dbabf6-b699-4d61-aa72-75105b2d828f
https://doi.org/10.1093/ehjcvp/pvad033 -
9
Autoren:
Quelle: Drug Saf
Schlagwörter: Glucose [MeSH], Pharmacology/Toxicology, Drug Interactions [MeSH], Humans [MeSH], Drug Safety and Pharmacovigilance, Muscular Diseases/chemically induced [MeSH], Sodium [MeSH], Letter to the Editor, Sodium-Glucose Transporter 2 Inhibitors/adverse effects [MeSH], Symporters [MeSH], Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects [MeSH], Glucose, Muscular Diseases, Symporters, Sodium, Humans, Drug Interactions, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Sodium-Glucose Transporter 2 Inhibitors
-
10
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Hart, H E, Kievits, O, Rutten, F H & Hollander, M H 2023, 'Evaluation of SGLT-2 inhibitor treatment in type 2 diabetes patients with very high cardiovascular risk', Primary care diabetes, vol. 17, no. 2, pp. 190-194. https://doi.org/10.1016/j.pcd.2023.02.001
Schlagwörter: Very high-risk patients, Type 2/diagnosis, Nutrition and Dietetics, Endocrinology, Diabetes and Metabolism, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, Type 2 diabetes, Practice guidelines, 3. Good health, Hypoglycemic Agents/adverse effects, 03 medical and health sciences, Primary care setting, 0302 clinical medicine, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2, Cardiovascular Diseases, Risk Factors, Heart Disease Risk Factors, Diabetes Mellitus, Internal Medicine, Humans, Hypoglycemic Agents, General practice, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases/diagnosis
Dateibeschreibung: application/pdf
-
11
Autoren: et al.
Quelle: Cardiovasc Diabetol
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-7 (2024)Schlagwörter: Male, Time Factors, Myocardial Infarction, Risk Assessment, 03 medical and health sciences, Diabetes mellitus, 0302 clinical medicine, Glucosides, Risk Factors, Recurrence, Sodium-glucose transporter 2 inhibitors, Diseases of the circulatory (Cardiovascular) system, Humans, Myocardial infarction, Type 2, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors, Aged, Research, Middle Aged, 3. Good health, Benzhydryl Compounds/therapeutic use [MeSH], Sodium-Glucose Transporter 2 Inhibitors/therapeutic use [MeSH], Aged [MeSH], Risk Assessment [MeSH], Diabetes Mellitus, Type 2/drug therapy [MeSH], Risk Factors [MeSH], Diabetes Mellitus, Type 2/mortality [MeSH], Male [MeSH], Myocardial Infarction/diagnosis [MeSH], Glucosides/adverse effects [MeSH], Sodium-Glucose Transporter 2 Inhibitors/adverse effects [MeSH], Diabetes Mellitus, Type 2/diagnosis [MeSH], Female [MeSH], Myocardial Infarction/mortality [MeSH], Benzhydryl Compounds/adverse effects [MeSH], Diabetes Mellitus, Type 2/complications [MeSH], Myocardial Infarction/prevention, Humans [MeSH], Treatment Outcome [MeSH], Middle Aged [MeSH], Time Factors [MeSH], Recurrence [MeSH], Myocardial Infarction/epidemiology [MeSH], Glucosides/therapeutic use [MeSH], Treatment Outcome, Diabetes Mellitus, Type 2, RC666-701, Female
-
12
Autoren: et al.
Weitere Verfasser: et al.
Quelle: N Engl J Med
Docusalut
Conselleria de Salut i Consum del Govern de les Illes BalearsSchlagwörter: Chronic/complications, Insuficiencia Renal Crónica, Progresión de la Enfermedad, Benzhydryl Compounds/adverse effects, Empagliflozin, Riñón, Diabetes Mellitus Tipo 2, Kidney, Article, 03 medical and health sciences, Cardiology, Chronic Kidney Disease, Clinical Medicine, Clinical Medicine General, Diabetes, Endocrinology, Nephrology, Prevention, 0302 clinical medicine, Creatinine/urine, Diabetes Mellitus, Humans, Renal Insufficiency, Benzhydryl Compounds, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, Enfermedades Cardiovasculares, 2. Zero hunger, Compuestos de Bencidrilo, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, Tasa de Filtración Glomerular, Cardiovascular Diseases/chemically induced, Type 2/complications, Humanos, 3. Good health, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Inhibidores del Cotransportador de Sodio-Glucosa 2, Creatinine, Disease Progression, Creatinina, empagliflozin, chronic renal disease, empa-kidney, chronic kidney disease, proteinuria, empagliflozin, Kidney/physiopathology, Glomerular Filtration Rate
Dateibeschreibung: application/pdf
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36331190
http://hdl.handle.net/20.500.13003/18576
https://hdl.handle.net/20.500.13003/18576
https://ora.ox.ac.uk/objects/uuid:f91f9722-f207-4d97-aa64-58636b323acc
https://doi.org/10.1056/nejmoa2204233
https://hdl.handle.net/11573/1674927
https://doi.org/10.1056/NEJMoa2204233 -
13
Autoren: et al.
Quelle: Cardiovasc Diabetol
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-12 (2024)Schlagwörter: Male, Time Factors, Linagliptin, Pulse Wave Analysis, Kidney, 03 medical and health sciences, Vascular Stiffness, 0302 clinical medicine, Glucosides, Diseases of the circulatory (Cardiovascular) system, Humans, Insulin, Diabetic Nephropathies, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors, Aged, PWV, Research, Middle Aged, Metformin, 3. Good health, Treatment Outcome, Diabetes Mellitus, Type 2, RC666-701, GFR decline, Female, Drug Therapy, Combination, Benzhydryl Compounds/therapeutic use [MeSH], Kidney/drug effects [MeSH], Sodium-Glucose Transporter 2 Inhibitors/therapeutic use [MeSH], Aged [MeSH], Diabetic Nephropathies/diagnosis [MeSH], Diabetes Mellitus, Type 2/physiopathology [MeSH], Sodium-Glucose Transporter 2 [MeSH], Diabetes Mellitus, Type 2/drug therapy [MeSH], Metformin/therapeutic use [MeSH], Kidney/physiopathology [MeSH], Hypoglycemic Agents/adverse effects [MeSH], Male [MeSH], Hypoglycemic Agents/therapeutic use [MeSH], Glucosides/adverse effects [MeSH], Clinical Relevance [MeSH], Drug Therapy, Combination [MeSH], SGLT2 inhibitors, Glomerular Filtration Rate/drug effects [MeSH], Sodium-Glucose Transporter 2 Inhibitors/adverse effects [MeSH], Diabetes Mellitus, Type 2/diagnosis [MeSH], Female [MeSH], Linagliptin/therapeutic use [MeSH], Benzhydryl Compounds/adverse effects [MeSH], Biomarkers/blood [MeSH], Humans [MeSH], Insulin [MeSH], Linagliptin/adverse effects [MeSH], Treatment Outcome [MeSH], Middle Aged [MeSH], Time Factors [MeSH], Diabetic Nephropathies/physiopathology [MeSH], Glucosides/therapeutic use [MeSH], Diabetic Nephropathies/drug therapy [MeSH], Pulse Wave Analysis [MeSH], Vascular Stiffness/drug effects [MeSH], Glomerular Filtration Rate
-
14
Autoren:
Quelle: Medicina Interna v.31 n.3 2024
Schlagwörter: Chemical and Drug Induced Liver Injury, Dapagliflozin, Sodium-Glucose Transporter 2 Inhibitors/adverse effects
Dateibeschreibung: text/html
-
15
Autoren: et al.
Quelle: Cardiovasc Diabetol
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-11 (2024)
Cardiovascular DiabetologySchlagwörter: Male, Blood Glucose, Time Factors, name=Internal Medicine, Risk Assessment, Body Mass Index, BMI variability, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Diseases of the circulatory (Cardiovascular) system, Humans, Diabetes management, Sodium-Glucose Transporter 2 Inhibitors/therapeutic use [MeSH], Type 2 diabetes, Aged [MeSH], Risk Assessment [MeSH], Cardiovascular disease, Cardiovascular Diseases/diagnosis [MeSH], Risk Factors [MeSH], Diabetes Mellitus, Type 2/mortality [MeSH], Randomized Controlled Trials as Topic [MeSH], 3P-MACE risk, HbA1c variability, Heart Disease Risk Factors [MeSH], Male [MeSH], Health outcomes, Cardiovascular Diseases/mortality [MeSH], Sodium-Glucose Transporter 2 Inhibitors/adverse effects [MeSH], Diabetes Mellitus, Type 2/diagnosis [MeSH], Female [MeSH], Diabetes Mellitus, Type 2/complications [MeSH], Biomarkers/blood [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Cardiovascular Diseases/epidemiology [MeSH], Middle Aged [MeSH], Diabetes Mellitus, Type 2/blood [MeSH], Time Factors [MeSH], Body Mass Index [MeSH], Glycated Hemoglobin/metabolism [MeSH], Research, Blood Glucose/metabolism [MeSH], Blood Glucose/drug effects [MeSH], Sodium-Glucose Transporter 2 Inhibitors, Aged, Randomized Controlled Trials as Topic, Glycated Hemoglobin, Middle Aged, 3. Good health, Diabetes and Metabolism, Treatment Outcome, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Heart Disease Risk Factors, RC666-701, Female, name=Endocrinology, Biomarkers, name=Cardiology and Cardiovascular Medicine
Dateibeschreibung: application/pdf
-
16
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Cardiovasc Diabetol
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-10 (2024)Schlagwörter: Male, 610 Medicine & health, Atrial flutter, 2705 Cardiology and Cardiovascular Medicine, Glucosides, Atrial Fibrillation, Diseases of the circulatory (Cardiovascular) system, Humans, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors, Aged, Heart Failure, Research, 1. No poverty, Sodium-glucose co-transporter 2 inhibitors(SGLT2i), Ventricular tachycardia, Stroke Volume, Middle Aged, Atrial fibrillation, 3. Good health, 2712 Endocrinology, Diabetes and Metabolism, Female [MeSH], Arrhythmia, Aged [MeSH], Benzhydryl Compounds [MeSH], Humans [MeSH], Ventricular Fibrillation [MeSH], Atrial Fibrillation [MeSH], Heart Failure [MeSH], Middle Aged [MeSH], Ventricular arrhythmia, Sudden cardiac death, Glucosides [MeSH], Male [MeSH], Death, Sudden, Cardiac/prevention, Stroke Volume [MeSH], Death, Sudden, Cardiac/etiology [MeSH], Sodium-Glucose Transporter 2 Inhibitors/adverse effects [MeSH], Novel Cardioprotective Antidiabetic Medications, Death, Sudden, Cardiac, 2724 Internal Medicine, RC666-701, Ventricular Fibrillation, 10209 Clinic for Cardiology, Female
Dateibeschreibung: ZORA258936.pdf - application/pdf
-
17
Autoren: et al.
Quelle: Cardiovasc Diabetol
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-12 (2024)Schlagwörter: Adolescent, Empagliflozin, Diabetes Mellitus, Type 2/epidemiology [MeSH], Type 2 diabetes, Medicare [MeSH], Aged [MeSH], United States [MeSH], Cardiovascular disease, Cardiovascular Diseases/diagnosis [MeSH], SGLT2i, Diabetes Mellitus, Type 2/drug therapy [MeSH], Heart Failure/epidemiology [MeSH], Hypoglycemic Agents/adverse effects [MeSH], Chronic kidney disease, Effectiveness, Sodium-Glucose Transporter 2 Inhibitors/adverse effects [MeSH], Diabetes Mellitus, Type 2/diagnosis [MeSH], Adolescent [MeSH], Benzhydryl Compounds [MeSH], Heart Failure/drug therapy [MeSH], Humans [MeSH], Cardiovascular Diseases/epidemiology [MeSH], Glucagon-Like Peptide-1 Receptor [MeSH], Stroke/prevention, Cardiovascular Diseases/prevention, GLP-1RA, Glucosides [MeSH], Glucagon-Like Peptide-1 Receptor Agonists [MeSH], Stroke/diagnosis [MeSH], Stroke/epidemiology [MeSH], Atherosclerosis/drug therapy [MeSH], Research, Heart Failure/diagnosis [MeSH], Novel Cardioprotective Antidiabetic Medications, Medicare, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, 0302 clinical medicine, Glucosides, Diseases of the circulatory (Cardiovascular) system, Humans, Hypoglycemic Agents, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors, Aged, Heart Failure, Atherosclerosis, United States, 3. Good health, Stroke, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, RC666-701
-
18
Autoren: et al.
Weitere Verfasser: et al.
Quelle: British Journal of Anaesthesia. 132:435-436
Schlagwörter: metabolic acidosis, Diabetes Mellitus, Ketosis, Humans, diabetes mellitus, Glucose, Sodium, *Diabetes Mellitus, Type 2/complications/drug therapy, *Sodium-Glucose Transporter 2 Inhibitors/adverse effects, *Ketosis, euglycaemic ketoacidosis, metabolic acidosis, side-effects, sodium-glucose cotransporter-2 inhibitor, [SDV]Life Sciences [q-bio], Sodium, Type 2/complications/drug therapy, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, [SDV] Life Sciences [q-bio], Glucose, Diabetes Mellitus, Type 2, diabetes mellitus, sodium-glucose cotransporter-2 inhibitor, side-effects, Humans, Sodium-Glucose Transporter 2 Inhibitors, euglycaemic ketoacidosis
-
19
Autoren: et al.
Weitere Verfasser: et al.
Quelle: NEW ENGLAND JOURNAL OF MEDICINE
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Bhatt, D L, Szarek, M, Pitt, B, Cannon, C P, Leiter, L A, McGuire, D K, Lewis, J B, Riddle, M C, Inzucchi, S E, Kosiborod, M N, Cherney, D Z I, Dwyer, J P, Scirica, B M, Bailey, C J, Díaz, R, Ray, K K, Udell, J A, Lopes, R D, Lapuerta, P, Steg, P G & SCORED Investigators 2021, 'Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease', The New England Journal of Medicine, vol. 384, no. 2, pp. 129-139. https://doi.org/10.1056/NEJMoa2030186Schlagwörter: Male, SAXAGLIPTIN, MELLITUS, 0302 clinical medicine, Renal Insufficiency, Glycosides, Chronic, 11 Medical and Health Sciences, RISK, SGLT2 INHIBITOR, OUTCOMES, EMPAGLIFLOZIN, Middle Aged, 3. Good health, Hospitalization, Cardiovascular Diseases, Medicine, HEART-FAILURE, Diarrhea/chemically induced, Female, OUTPATIENTS, Life Sciences & Biomedicine, Type 2, Diarrhea, Mycoses/etiology, SCORED Investigators, Renal Insufficiency, Chronic/complications, General & Internal, Glycosides/adverse effects, Diabetic Ketoacidosis, 03 medical and health sciences, Medicine, General & Internal, Sodium-Glucose Transporter 1, Double-Blind Method, General & Internal Medicine, Diabetes Mellitus, Humans, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, Hospitalization/statistics & numerical data, Aged, Science & Technology, Diabetic Ketoacidosis/chemically induced, Cardiovascular Diseases/epidemiology, Diabetes Mellitus, Type 2/complications, MORTALITY, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, Settore MED/13 - ENDOCRINOLOGIA, CARDIOVASCULAR EVENT RATES, Sodium-Glucose Transporter 1/antagonists & inhibitors, Diabetes Mellitus, Type 2, Mycoses
Dateibeschreibung: application/pdf
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/33200891
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16116
https://incliva.fundanetsuite.com/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16116
https://publications.aston.ac.uk/id/eprint/42285/1/nejmoa2030186.pdf
https://spiral.imperial.ac.uk/handle/10044/1/84257
https://research.aston.ac.uk/en/publications/sotagliflozin-in-patients-with-diabetes-and-chronic-kidney-diseas
http://europepmc.org/abstract/MED/33200891
https://pubmed.ncbi.nlm.nih.gov/33200891/
https://utsouthwestern.pure.elsevier.com/en/publications/sotagliflozin-in-patients-with-diabetes-and-chronic-kidney-diseas
https://www.nejm.org/doi/suppl/10.1056/NEJMoa2030186/suppl_file/nejmoa2030186_appendix.pdf
http://hdl.handle.net/10044/1/84257
https://pure.au.dk/portal/en/publications/6bc50c6b-8a7a-4eea-bd9e-9032680e8b64
https://pure.au.dk/portal/en/publications/6bc50c6b-8a7a-4eea-bd9e-9032680e8b64
https://doi.org/10.1056/NEJMoa2030186
https://pure.au.dk/ws/files/275345883/Sotagliflozin_in_Patients_with_Diabetes_and_Chronic_Kidney_Disease.pdf -
20
Autoren: et al.
Quelle: BMJ. :e080257
Schlagwörter: Adult, Renal Insufficiency, Chronic / complications, Hypoglycemic Agents / adverse effects, Sodium-Glucose Transporter 2 Inhibitors / therapeutic use, Sodium-Glucose Transporter 2 Inhibitors / adverse effects, Diabetes Mellitus, Type 2, Hypoglycemic Agents / therapeutic use, Cardiovascular Diseases, Disease Progression, Diabetes Mellitus, Type 2 / complications, Humans, Hypoglycemic Agents, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2 / drug therapy, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases / prevention & control
Dateibeschreibung: application/pdf
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39353639
Nájsť tento článok vo Web of Science 
Full Text Finder 
Full Text